SCHEMBL14769820

SCHEMBL14769820

COc1nc(=O)n(C(C)C)cc1C

nearest known ligand 0.36

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.36
LMNA P02545 1/20 0.36
MAT2A P31153 1/20 0.34
CYP2C9 P11712 1/20 0.31
KCNH2 Q12809 1/20 0.31
MAP3K5 Q99683 1/20 0.31
GAA P10253 1/20 0.30
HPGD P15428 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL784611 0.81 ALDH1A1 (0.34) ALDH1A1HPGDSMN1; SMN2
SCHEMBL21392460 0.80 LMNA (0.33) LMNA
SCHEMBL24371256 0.78 MAT2A (0.36) ALDH1A1LMNAMAT2AGAAHPGD
SCHEMBL20782379 0.76 MAT2A (0.36) ALDH1A1LMNAMAT2AGAAHPGD
SCHEMBL15032497 0.74
SCHEMBL12206794 0.74 ADORA2A (0.36) MAP3K5SMN1; SMN2
SCHEMBL14769830 0.73 SMN1; SMN2 (0.33) SMN1; SMN2
SCHEMBL12194501 0.71 MAT2A (0.34) ALDH1A1LMNAMAT2AGAAHPGD
SCHEMBL17282462 0.71 KDM4E (0.33) SMN1; SMN2
SCHEMBL15703049 0.69 LRRK2 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773132-B2 Cyclic di-nucleotides as stimulator of interferon genes modulators BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) 2023-10-03 US disclosed
US-20200331957-A1 CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS AJ SCIENCES (YIXING) CO., LTD (CN) 2020-10-22 US disclosed
US-9403863-B2 Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections IDENIX PHARMACEUTICALS LLC (US) 2016-08-02 US disclosed
US-20130064794-A1 Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections IDENIX PHARMACEUTICALS, INC. (US) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200331957-A1 CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS STING1, IRF3, CGAS ALDH1A1 3483/4885LMNA 4707/4885MAT2A 619/4885
US-11773132-B2 Cyclic di-nucleotides as stimulator of interferon genes modulators STING1, IRF3, CGAS ALDH1A1 3483/4885LMNA 4707/4885MAT2A 619/4885
US-20130064794-A1 Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections PYGL, HAVCR2, PNP ALDH1A1 1186/4885LMNA 1432/4885MAT2A 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.